Takeda Pharmaceutical Company Limited (LON: 0A87)
London
· Delayed Price · Currency is GBP · Price in USD13.12
+0.10 (0.77%)
At close: Dec 20, 2024
Takeda Pharmaceutical Company Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 29, 2024 | Mar '24 Mar 30, 2024 | Mar '23 Mar 30, 2023 | Mar '22 Mar 30, 2022 | Mar '21 Mar 30, 2021 | Mar '20 Mar 30, 2020 | 2019 - 2015 |
| Revenue | 4,546,083 | 4,263,762 | 4,027,478 | 3,569,006 | 3,197,812 | 3,291,188 | Upgrade
|
| Revenue Growth (YoY) | 9.43% | 5.87% | 12.85% | 11.61% | -2.84% | 56.93% | Upgrade
|
| Cost of Revenue | 1,548,074 | 1,431,505 | 1,253,163 | 1,127,308 | 1,013,655 | 1,120,146 | Upgrade
|
| Gross Profit | 2,998,009 | 2,832,257 | 2,774,315 | 2,441,698 | 2,184,157 | 2,171,042 | Upgrade
|
| Selling, General & Admin | 1,091,066 | 1,053,819 | 997,234 | 886,327 | 875,514 | 964,268 | Upgrade
|
| Research & Development | 725,957 | 728,617 | 633,325 | 526,087 | 455,765 | 492,088 | Upgrade
|
| Other Operating Expenses | -17,732 | 35,059 | 38,987 | 10,433 | 23,602 | 10,663 | Upgrade
|
| Operating Expenses | 2,344,384 | 2,339,020 | 2,154,648 | 1,841,636 | 1,760,110 | 1,874,362 | Upgrade
|
| Operating Income | 653,625 | 493,237 | 619,667 | 600,062 | 424,047 | 296,680 | Upgrade
|
| Interest Expense | -119,122 | -115,392 | -116,973 | -122,432 | -130,806 | -149,010 | Upgrade
|
| Interest & Investment Income | 21,401 | 11,628 | 5,781 | 4,763 | 2,153 | 12,646 | Upgrade
|
| Earnings From Equity Investments | 3,619 | 6,473 | -8,630 | -15,367 | 76 | -23,987 | Upgrade
|
| Currency Exchange Gain (Loss) | -13,612 | -13,612 | -9,729 | -3,903 | -15,575 | 10,979 | Upgrade
|
| Other Non Operating Income (Expenses) | -30,814 | -31,520 | 3,975 | -26,119 | 1,118 | -10,631 | Upgrade
|
| EBT Excluding Unusual Items | 515,097 | 350,814 | 494,091 | 437,004 | 281,013 | 136,677 | Upgrade
|
| Merger & Restructuring Charges | -104,487 | -81,358 | -59,234 | -83,836 | -115,875 | -181,831 | Upgrade
|
| Gain (Loss) on Sale of Investments | -18,320 | - | 22,416 | 8,482 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 14,075 | 7,975 | 8,901 | 8,164 | 235,117 | 19,871 | Upgrade
|
| Asset Writedown | -51,821 | -139,809 | -62,484 | -54,421 | -17,521 | -60,974 | Upgrade
|
| Legal Settlements | -45,212 | -45,212 | -16,455 | -20,319 | -17,401 | - | Upgrade
|
| Other Unusual Items | -39,619 | -39,619 | -12,145 | 7,497 | 902 | 17,224 | Upgrade
|
| Pretax Income | 269,713 | 52,791 | 375,090 | 302,571 | 366,235 | -60,754 | Upgrade
|
| Income Tax Expense | -20,454 | -91,406 | 58,052 | 72,405 | -9,936 | -105,044 | Upgrade
|
| Earnings From Continuing Operations | 290,167 | 144,197 | 317,038 | 230,166 | 376,171 | 44,290 | Upgrade
|
| Minority Interest in Earnings | -171 | -130 | -21 | -107 | -166 | -49 | Upgrade
|
| Net Income | 289,996 | 144,067 | 317,017 | 230,059 | 376,005 | 44,241 | Upgrade
|
| Net Income to Common | 289,996 | 144,067 | 317,017 | 230,059 | 376,005 | 44,241 | Upgrade
|
| Net Income Growth | 51.33% | -54.56% | 37.80% | -38.81% | 749.90% | -67.28% | Upgrade
|
| Shares Outstanding (Basic) | 1,572 | 1,564 | 1,552 | 1,564 | 1,562 | 1,557 | Upgrade
|
| Shares Outstanding (Diluted) | 1,593 | 1,580 | 1,570 | 1,577 | 1,574 | 1,566 | Upgrade
|
| Shares Change (YoY) | 1.07% | 0.67% | -0.46% | 0.23% | 0.47% | 61.98% | Upgrade
|
| EPS (Basic) | 184.47 | 92.09 | 204.29 | 147.14 | 240.72 | 28.41 | Upgrade
|
| EPS (Diluted) | 182.01 | 91.16 | 201.94 | 145.87 | 238.96 | 28.25 | Upgrade
|
| EPS Growth | 49.73% | -54.86% | 38.44% | -38.96% | 745.88% | -79.80% | Upgrade
|
| Free Cash Flow | 677,776 | 540,924 | 836,499 | 999,853 | 899,725 | 542,670 | Upgrade
|
| Free Cash Flow Per Share | 425.38 | 342.28 | 532.85 | 633.95 | 571.79 | 346.49 | Upgrade
|
| Dividend Per Share | 192.000 | 188.000 | 180.000 | 180.000 | 180.000 | 180.000 | Upgrade
|
| Dividend Growth | 4.35% | 4.44% | 0% | 0% | 0% | 0% | Upgrade
|
| Gross Margin | 65.95% | 66.43% | 68.88% | 68.41% | 68.30% | 65.97% | Upgrade
|
| Operating Margin | 14.38% | 11.57% | 15.39% | 16.81% | 13.26% | 9.01% | Upgrade
|
| Profit Margin | 6.38% | 3.38% | 7.87% | 6.45% | 11.76% | 1.34% | Upgrade
|
| Free Cash Flow Margin | 14.91% | 12.69% | 20.77% | 28.01% | 28.14% | 16.49% | Upgrade
|
| EBITDA | 1,328,561 | 1,137,698 | 1,210,650 | 1,183,213 | 983,718 | 880,329 | Upgrade
|
| EBITDA Margin | 29.22% | 26.68% | 30.06% | 33.15% | 30.76% | 26.75% | Upgrade
|
| D&A For EBITDA | 674,936 | 644,461 | 590,983 | 583,151 | 559,671 | 583,649 | Upgrade
|
| EBIT | 653,625 | 493,237 | 619,667 | 600,062 | 424,047 | 296,680 | Upgrade
|
| EBIT Margin | 14.38% | 11.57% | 15.39% | 16.81% | 13.26% | 9.01% | Upgrade
|
| Effective Tax Rate | - | - | 15.48% | 23.93% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.